33 documents found, page 1 of 4
A Portuguese expert panel position paper on the management of heart failure wit...
Silva-Cardoso, José; Moreira, Emília; Melo, Rachel Tavares de; Moraes-Sarmento, Pedro; Cardim, Nuno; Oliveira, Mário; Gavina, Cristina; Moura, BrendaIn Portugal, a 15.2% prevalence of heart failure with preserved ejection fraction (HFpEF) was recently identified among those aged ≥50 years. HFpEF represents 90% of Portuguese heart failure patients. HFpEF management in Portugal is challenging due to patient heterogeneity, diagnostic and therapeutic complexity, and organizational constraints on the healthcare system. Considering the above, a panel of Portugues...
A Portuguese expert panel position paper on the management of heart failure wit...
Silva-Cardoso, José; Moreira, Emília; Melo, Rachel Tavares de; Moraes-Sarmento, Pedro; Cardim, Nuno; Oliveira, Mário; Gavina, Cristina; Moura, BrendaHeart failure (HF) with preserved ejection fraction (HFpEF) affects more than 50% of HF patients worldwide, and more than 70% of HF patients aged over 65. This is a complex syndrome with a clinically heterogeneous presentation and a multifactorial pathophysiology, both of which make its diagnosis and treatment challenging. A Portuguese HF expert panel convened to address HFpEF pathophysiology and therapy, as we...
Correction to: worsening heart failure: progress, pitfalls, and perspectives (H...
Fonseca, Cândida; Baptista, Rui; Franco, Fátima; Moura, Brenda; Pimenta, Joana; Sarmento, Pedro Moraes; Cardoso, José Silva; Brito, DulceThe order of the authors' first and last names was reversed in the original publication. The correct author names are as follows: Incorrect Author List: Fonseca Cândida · Baptista Rui · Franco Fátima · Moura Brenda · Pimenta Joana · Pedro Moraes Sarmento · Silva Cardoso José · Brito Dulce Correct Author List: Cândida Fonseca · Rui Baptista · Fátima Franco · Brenda Moura · Joana Pimenta · Pedro Moraes Sarmento ·...
A Portuguese Expert Panel Position Paper on the Management of Heart Failure wit...
Silva-Cardoso, José; Moreira, Emília; Tavares de Melo, Rachel; Moraes-Sarmento, Pedro; Cardim, Nuno; Oliveira, Mário; Gavina, Cristina; Moura, BrendaIn Portugal, a 15.2% prevalence of heart failure with preserved ejection fraction (HFpEF) was recently identified among those aged ≥50 years. HFpEF represents 90% of Portuguese heart failure patients. HFpEF management in Portugal is challenging due to patient heterogeneity, diagnostic and therapeutic complexity, and organizational constraints on the healthcare system. Considering the above, a panel of Portugues...
Worsening heart failure: progress, pitfalls, and perspectives
Fonseca, Cândida; Baptista, Rui; Franco, Fátima; Moura, Brenda; Pimenta, Joana; Moraes Sarmento, Pedro; Cardoso, José Silva; Brito, DulceFor most patients with chronic heart failure (HF), the clinical course of the disease includes periods of apparent clinical stability punctuated by episodes of clinical deterioration with worsening signs and symptoms, a condition referred to as worsening heart failure (WHF). Over time, episodes of WHF may become more frequent, and patients may enter a cycle of recurrent events associated with deterioration in t...
A Portuguese expert panel position paper on the management of heart failure wit...
Silva-Cardoso, José; Moreira, Emília; Tavares de Melo, Rachel; Moraes-Sarmento, Pedro; Cardim, Nuno; Oliveira, Mario; Gavina, Cristina; Moura, BrendaHeart failure (HF) with preserved ejection fraction (HFpEF) affects more than 50% of HF patients worldwide, and more than 70% of HF patients aged over 65. This is a complex syndrome with a clinically heterogeneous presentation and a multifactorial pathophysiology, both of which make its diagnosis and treatment challenging. A Portuguese HF expert panel convened to address HFpEF pathophysiology and therapy, as we...
World Heart Federation cholesterol roadmap: the Portuguese case
Abreu, Ana; Dores, Hélder; Gonçalves, Lino; Franco, Fátima; Silveira, Conceição; Proença, Gonçalo; Timóteo, Ana Teresa; Cardim, Nuno; Pedro, MónicaAtherosclerotic cardiovascular disease (ASCVD) remains the major cause of premature death and disability; effective cardiovascular (CV) risk prevention is fundamental. The World Heart Federation (WHF) Cholesterol Roadmap provides a framework for national policy development and aims to achieve ASCVD prevention. At the invitation of the WHF, a group of experts from the Portuguese Society of Cardiology (SPC), addr...
Acute Inferior Myocardial Infarction: Beyond the ST-Segment Elevation
Rocha, Diana; Simões, Pedro; Gouveia, João; Ferreira, Cátia; Franco, FátimaAcute coronary syndromes (ACS) are considered a continuum, enclosing both non-ST-elevation (NSTE)-ACS, including unstable angina and non-ST-elevation myocardial infarction (NSTEMI), and ST-elevation myocardial infarction (STEMI). The diagnosis of myocardial infarction (MI) is associated with troponin release. Classification of MI has fundamentally been based on the presence or absence of ST-segment elevation (S...
Perceptions of cardiology, professional preferences and impact on career choice...
Timóteo, Ana Teresa; Ribeiras, Regina; Gavina, Cristina; Cabral, Sofia; Almeida, Ana G.; António, Natália; Calé, Rita; Moura, Brenda; Franco, FátimaIntroduction and objectives: Cardiology has not been seen as an attractive specialty, and women have avoided it for many years. Some surveys have been performed in other countries, but in Portugal, the situation is largely unknown. Methods: An online survey on perceptions of cardiology and professional preferences was sent to 1371 members of the Portuguese Society of Cardiology, of whom 18.2% completed the surv...
Beyond clinical trials: the cost saving associated with Dapagliflozin use in Po...
Brito, Dulce; Fonseca, Cândida; Franco, Fátima; Lopes, Vanessa; Gonçalves, Sara; Baptista, Rui; Sequeira, Joana; Marques, Irene; Rego, RitaIntroduction and objectives: Heart failure (HF) is a clinical syndrome associated with substantial morbidity, mortality, and healthcare costs. Dapagliflozin has proven efficacy in reducing the risk of death and hospitalization in HF patients, regardless of left ventricular ejection fraction (LVEF). This paper aimed to project the potential impact of dapagliflozin on healthcare costs related to HF subsequent hos...